Cytokinetics vs Wave Life Sciences
Cytokinetics is the larger business, with $88.0m of revenue in fiscal 2025 against $42.7m for Wave Life Sciences (2.1 times as much). Cytokinetics grew faster (376.6% against -60.5%). Wave Life Sciences kept more of each dollar of sales as profit: a net margin of -478.3% against -891.6%.
| Latest fiscal year | CytokineticsCYTK, 2025 | Wave Life SciencesWVE, 2025 |
|---|---|---|
| Revenue | $88.0m | $42.7m |
| Revenue growth | 376.6% | -60.5% |
| Net income | −$785m | −$204m |
| Operating margin | -695.4% | — |
| Net margin | -891.6% | -478.3% |
| Return on equity | — | -56.2% |
| Free cash flow | −$535m | −$188m |
| Cash | $123m | $602m |
| Total debt | $999m | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 673 | 317 |
| Market value | $7.69bn | $707m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 85 sales | 6 buys, 46 sales |